Cited by 694Cannabis and Cannabinoid ResearchAdipokines, Inflammation, and Metabolic DiseasesRegulation of Appetite and Obesity

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Activation of the Peripheral Endocannabinoid System in Human Obesity

Open access

Engeli, Stefan, Böhnke, Jana, Feldpausch, Mareike, Gorzelniak, Kerstin, Janke, Jürgen, Bátkai, Sándor, Pacher, Pál, Harvey-White, Judy, Luft, Friedrich C., Sharma, Arya M., Jordan, Jens·2005·Diabetes

DOI 10.2337/diabetes.54.10.2838PMC PMC2228268

Open this paper in CoChat — free account Open PDF

Abstract

Obesity is the main risk factor for the development of type 2 diabetes. Activation of the central endocannabinoid system increases food intake and promotes weight gain. Blockade of the cannabinoid type 1 (CB-1) receptor reduces body weight in animals by central and peripheral actions; the role of the peripheral endocannabinoid system in human obesity is now being extensively investigated. We measured circulating endocannabinoid concentrations and studied the expression of CB-1 and the main degrading enzyme, fatty acid amide hydrolase (FAAH), in adipose tissue of lean (n = 20) and obese (n = 20) women and after a 5% weight loss in a second group of women (n = 17). Circulating levels of anandamide and 1/2-arachidonoylglycerol were increased by 35 and 52% in obese compared with lean women (P < 0.05). Adipose tissue mRNA levels were reduced by -34% for CB-1 and -59% for FAAH in obese subjects (P < 0.05). A strong negative correlation was found between FAAH expression in adipose tissue and circulating endocannabinoids. Circulating endocannabinoids and CB-1 or FAAH expression were not affected by 5% weight loss. The expression of CB-1 and FAAH was increased in mature human adipocytes compared with in preadipocytes and was found in several human tissues. Our findings support the presence of a peripheral endocannabinoid system that is upregulated in human obesity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2337/diabetes.54.10.2838

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery
Sjöström, L., Lindroos, A.-K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Dahlgren, S., Larsson, B., Narbro, K., Sjöström, C. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035622 · Cited by 4,457
Unresponsiveness to Cannabinoids and Reduced Addictive Effects of Opiates in CB 1 Receptor Knockout Mice
Ledent, C. A., Valverde, O., Cossu, G., Petitet, F., Aubert, J.-F., Beslot, F., Böhme, G. A., Impérato, A., Pedrazzini, T., Roques, B. P., et al. (1999) · Science · doi:10.1126/science.283.5400.401 · Cited by 3,628
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957
Leptin-regulated endocannabinoids are involved in maintaining food intake
Di Marzo, V., Goparaju, S. K., Wang, L., Liu, J., Bátkai, S., Járai, Z., Fezza, F., Miura, G. I., Palmiter, R. D., Sugiura, T., et al. (2001) · Nature · doi:10.1038/35071088 · Cited by 1,559
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
Gaal, L. F. V., Rissanen, A., Scheen, A. J., Ziegler, O., & Rössner, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66374-x · Cited by 1,511
The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis
Cota, D., Marsicano, G., Tschöp, M. H., Grübler, Y., Flachskamm, C., Schubert, M. I., Auer, D. P., Yassouridis, A., Thöne‐Reineke, C., Ortmann, S., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17725 · Cited by 1,168
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity
Osei‐Hyiaman, D., DePetrillo, M. A., Pacher, P., Liu, J., Radaeva, S., Bátkai, S., Harvey-White, J. D., Mackie, K., Offertáler, L., Wang, L., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23057 · Cited by 1,131
Body Mass Index, Waist Circumference, and Health Risk
Janssen, I., Katzmarzyk, P. T., & Ross, R. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2074 · Cited by 969

Show all 37 references

Sorted by citations

Items 301–400 of 694

CB1 Cannabinoid Receptor Inhibition: Promising Approach for Heart Failure?
Mukhopadhyay, P., Rajesh, M., Bátkai, S., & Pacher, P. (2008) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2008.00016.x · Cited by 33
Cannabinoid CB1 receptor activation stimulates neurite outgrowth and inhibits capsaicin-induced Ca2+ influx in an in vitro model of diabetic neuropathy
Zhang, F., Challapalli, S. C., & Smith, P. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.04.017 · Cited by 33
CB1 blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans
Bergholm, R., Sevastianova, K., Santos, A., Kotronen, A., Urjansson, M., Hakkarainen, A., Lundbom, J., Tiikkainen, M., Rissanen, A., Lundbom, N. M. I., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.116 · Cited by 33
Changes in Plasma Levels of N-Arachidonoyl Ethanolamine and N-Palmitoylethanolamine following Bariatric Surgery in Morbidly Obese Females with Impaired Glucose Homeostasis
Mallipedhi, A., Prior, S. L., Dunseath, G. J., Bracken, R. M., Barry, J. D., Caplin, S., Eyre, N., Morgan, J. P., BAXTER, J. N., O’Sullivan, S. E., et al. (2015) · Journal of Diabetes Research · doi:10.1155/2015/680867 · Cited by 33
“Of interest, a modest weight loss of 5% by diet or medication (sibutramine) did not influence circulating EC levels in postmenopausal women or obese subjects, respectively [11, 26], whereas a 10% weight reduction in abdominally obese men was associated with a reduction in 2-AG levels [27].”
BackgroundResult
Dysregulation of endocannabinoid concentrations in human subcutaneous adipose tissue in obesity and modulation by omega-3 polyunsaturated fatty acids
Fisk, H. L., Childs, C. E., Miles, E. A., Ayres, R., Noakes, P. S., Paras-Chavez, C., Kuda, O., Kopecký, J., Antoun, E., Lillycrop, K. A., et al. (2021) · Clinical Science · doi:10.1042/cs20201060 · Cited by 32
The activity of the endocannabinoid metabolising enzyme fatty acid amide hydrolase in subcutaneous adipocytes correlates with BMI in metabolically healthy humans
Cable, J. C., Tan, G. D., Alexander, S. P. H., & O’Sullivan, S. E. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-129 · Cited by 31
“This hypothesis is supported by the recent finding that AEA levels in subcutaneous adipose tissue are not different between lean and non-diabetic obese humans [30].”
Influential
The dysregulation of the endocannabinoid system in diabesity—a tricky problem
Scherer, T., & Buettner, C. (2009) · Journal of Molecular Medicine · doi:10.1007/s00109-009-0459-y · Cited by 32
“FAAH expression in WAT negatively correlates with elevated AEA plasma concentrations in obese human subjects [22].”
Background
Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin
Bifulco, M. (2009) · Oncology Reports · doi:10.3892/or_00000619 · Cited by 32
Variants in the CNR1 and the FAAH Genes and Adiposity Traits in the Community
Lieb, W., Manning, A. K., Florez, J. C., Dupuis, J., Cupples, L. A., McAteer, J. B., Vasan, R. S., Hoffmann, U., O’Donnell, C. J., Meigs, J. B., et al. (2009) · Obesity · doi:10.1038/oby.2008.608 · Cited by 32
“A negative correlation between adipose tissue FAAH expression and circulating endocannabinoid levels has been observed (25).”
Background
A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents
Sharma, M. K., Murumkar, P. R., Barmade, M. A., Giridhar, R., & Yadav, M. R. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1064898 · Cited by 31
“The detailed description of these actions can be found elsewhere [33-38].”
Background
Endocannabinoid crosstalk between placenta and maternal fat in a baboon model (Papio spp.) of obesity
Brocato, B. E., Zoerner, A. A., Janjetović, Z., Skobowiat, C., Gupta, S., Moore, B. M., II, Slominski, A. T., Zhang, J., Schenone, M., Phinehas, R., et al. (2013) · Placenta · doi:10.1016/j.placenta.2013.08.007 · Cited by 31
Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs
Richey, J. M., Woolcott, O. O., Stefanovski, D., Harrison, L. N., Zheng, D., Lottati, M., Hsu, I. R., Kim, S. P., Kabir, M., Catalano, K. J., et al. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90972.2008 · Cited by 32
“The expression of CB1R has been found in both rodent (1, 6) and human (10, 32, 38) adipocytes.”
Background
Cannabinoid Receptors in Metabolic Regulation and Diabetes
Rohbeck, E., Eckel, J., & Romacho, T. (2021) · Physiology · doi:10.1152/physiol.00029.2020 · Cited by 32
Appetite and Metabolic Effects of Ghrelin and Cannabinoids: Involvement of AMP-Activated Protein Kinase
van Thuijl, H., Kola, B., & Korbonits, M. (2007) · Vitamins and hormones · doi:10.1016/s0083-6729(06)77006-6 · Cited by 31
The endocannabinoid system in appetite regulation and treatment of obesity
Kurtov, M., Rubinić, I., & Likić, R. (2024) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70009 · Cited by 30
“14,26,67 An overview of the studies on the ECS and its impact on food intake, energy metabolism, and obesity is presented in Table 1.”
Background
Diagnosing Impaired Glucose Tolerance Using Direct Infusion Mass Spectrometry of Blood Plasma
Lokhov, P. G., Trifonova, O. P., Maslov, D. L., Balashova, E. E., Archakov, A. I., Shestakova, E. A., Shestakova, M. V., & Dedov, I. I. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105343 · Cited by 30
“For example, activation of the endocannabinoid system has been shown to increase food intake, promote weight gain [27,28], and can also contribute to the worsening of a cardiovascular profile (i.”
Background
Decreased circulating anandamide levels in preeclampsia
Molvarec, A., Fügedi, G., Szabó, E., Stenczer, B., Walentin, S., & Rigó, J. J. (2015) · Hypertension Research · doi:10.1038/hr.2015.20 · Cited by 31
CB1R regulates soluble leptin receptor levels via CHOP, contributing to hepatic leptin resistance
Drori, A., Gammal, A., Azar, S., Hinden, L., Hadar, R., Wesley, D., Nemirovski, A., Szanda, G., Salton, M., Tirosh, B., et al. (2020) · eLife · doi:10.7554/elife.60771 · Cited by 30
“The eCB/CB1R system is highly overactive during obesity (Engeli, 2008; Engeli et al., 2005; Matias et al., 2006; Monteleone et al., 2005), and both central and peripheral stimulations of this system have been suggested to contribute to the development of the metabolic syndrome, including leptin resistance (Engeli et a…”
Background
Functional Fine-Tuning of Metabolic Pathways by the Endocannabinoid System—Implications for Health and Disease
Moreno, E., Cavic, M. R., & Canela, E. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073661 · Cited by 30
The endocannabinoid system: Body weight and metabolic regulation
Engeli, S., & Jordan, J. (2006) · Clinical cornerstone · doi:10.1016/s1098-3597(06)80041-4 · Cited by 32
Overactivation of the endocannabinoid system alters the antilipolytic action of insulin in mouse adipose tissue
Muller, T., Demizieux, L., Troy-Fioramonti, S., Gresti, J., de Barros, J.-P. P., Berger, H., Vergès, B. L., & Degrace, P. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00374.2016 · Cited by 29
“At the same time, it is now well established that obesity is associated with overactivation of the endocannabinoid system (ECS) (20, 21, 47).”
Background
Update on therapeutic strategies to increase adiponectin function and secretion in metabolic syndrome
Montecucco, F., & Mach, F. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00986.x · Cited by 29
Peripheral Effects of FAAH Deficiency on Fuel and Energy Homeostasis: Role of Dysregulated Lysine Acetylation
Vaitheesvaran, B., Yang, L., Hartil, K., Glaser, S. T., Yazulla, S., Bruce, J. E., & Kurland, I. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033717 · Cited by 29
“Several studies have shown that the endocannabinoid system is dysregulated [7,8,9,10] and activated in peripheral tissues [11,12,13] during obesity.”
Background
Beneficial effect of a chronic treatment with rimonabant on pancreatic function and β-cell morphology in Zucker Fatty rats
Duvivier, V., Delafoy-Plasse, L., Delion, V., Lechevalier, P., Bail, J.-C. L., Guillot, E., Pruniaux, M., & Galzin, A. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.05.024 · Cited by 29
“Recent data demonstrate increased 2-arachidonoylglycerol and anandamide levels in obese (Engeli et al., 2005) and type 2 diabetic (Matias et al.”
Gut microbiota and oleoylethanolamide in the regulation of intestinal homeostasis
Filippo, C. D., Costa, A., Becagli, M. V., Monroy, M. M., Provensi, G., & Passani, M. B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1135157 · Cited by 29
“Obesity is also characterized by a relevant increase of endocannabinoids levels in both plasma and adipose tissue, decreased expression of FAAH, and altered expression of cannabinoid receptor 1 (CB1) (80).”
BackgroundInfluential
Novel pyrazole-3-carboxamide derivatives as cannabinoid-1 (CB1) antagonists: Journey from non-polar to polar amides
Sasmal, P. K., Reddy, D. S., Talwar, R., Venkatesham, B., Balasubrahmanyam, D., Kannan, M., Srinivas, P., Kyasa, S. K., Devi, B. N., Jadhav, V. P., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.10.055 · Cited by 28
Endocannabinoid system overactivity and the metabolic syndrome: Prospects for treatment
Perkins, J. M., & Davis, S. N. (2008) · Current Diabetes Reports · doi:10.1007/s11892-008-0004-3 · Cited by 28
Endocannabinoids, Blood Pressure and the Human Heart
Sarzani, R. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01677.x · Cited by 28
“First, the available evidence indicates that an overactivation of the ECS is present in human obesity ( 18 ).”
BackgroundResult
Measuring Visceral and Hepatic Fat in Clinical Practice and Clinical Research
Naboush, A., & Hamdy, O. (2013) · Endocrine Practice · doi:10.4158/ep12331.or · Cited by 27
Differential modulation of white adipose tissue endocannabinoid levels by n-3 fatty acids in obese mice and type 2 diabetic patients
Rossmeisl, M., Pavlišová, J., Janovská, P., Kuda, O., Bardová, K., Hansíková, J., Svobodová, M., Oseeva, M., Veleba, J., Kopecký, J., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2018.03.011 · Cited by 27
Endocannabinoids as potential biomarkers: It‘s all about pre-analytics
Kratz, D., Thomas, D., & Gurke, R. (2021) · Journal of Mass Spectrometry and Advances in the Clinical Lab · doi:10.1016/j.jmsacl.2021.11.001 · Cited by 27
A Selective Cannabinoid-1 Receptor Antagonist, PF-95453, Reduces Body Weight and Body Fat to a Greater Extent than Pair-Fed Controls in Obese Monkeys
Wagner, J. D., Zhang, L., Kavanagh, K., Ward, G. M., Chin, J. E., Hadcock, J. R., Auerbach, B. J., & Harwood, H. J. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.168187 · Cited by 27
Inhibition of cannabinoid CB1 receptor upregulates Slc2a4 expression via nuclear factor-κB and sterol regulatory element-binding protein-1 in adipocytes
Furuya, D. T., Poletto, A. C., Freitas, H. S., & Machado, U. F. (2012) · Journal of Molecular Endocrinology · doi:10.1530/jme-12-0037 · Cited by 27
The Fat Side of the Endocannabinoid System: Role of Endocannabinoids in the Adipocyte
Matias, I., Belluomo, I., & Cota, D. (2016) · Cannabis and Cannabinoid Research · doi:10.1089/can.2016.0014 · Cited by 30
“31,40 Of note, circulating EC levels are associated with body fat distribution.”
Chemical Tools for Studying Lipid-Binding Class A G Protein–Coupled Receptors
Cooper, A. G., Singh, S., Hook, S. M., Tyndall, J. D. A., & Vernall, A. J. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.013243 · Cited by 26
“CB1 receptor is abundant in the brain, particularly on central and peripheral neurons in the presynapse (Kano et al., 2009), postsynaptic cells, and astrocytes (Castillo et al., 2012), and is found in low levels in peripheral organs (Engeli et al., 2005).”
Background
Circulating endocannabinoid concentrations during orthostatic stress
Schroeder, C., Batkai, S., Engeli, S., Tank, J., Diedrich, A., Luft, F. C., & Jordan, J. (2009) · Clinical Autonomic Research · doi:10.1007/s10286-009-0026-1 · Cited by 26
“The observation cannot be explained by confounding influences of age, gender, or body composition [3, 6].”
BackgroundSelf-citation
The endocrine disruptor DEHP and the ECS: analysis of a possible crosstalk
Ernst, J., Grabiec, U., Falk, K., Dehghani, F., & Schaedlich, K. (2020) · Endocrine Connections · doi:10.1530/ec-19-0548 · Cited by 26
Cannabinoid receptor 1 expression is higher in muscle of old vs. young males, and increases upon resistance exercise in older adults
Dalle, S., & Koppo, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-97859-3 · Cited by 26
Lipid endocannabinoids in energy metabolism, stress and developmental programming
de Almeida, M. M., Dias-Rocha, C. P., Calviño, C., & Trevenzoli, I. H. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111522 · Cited by 27
Molecular networks underlying cannabinoid signaling in skeletal muscle plasticity
Dalle, S., Schouten, M., Meeus, G., Slagmolen, L., & Koppo, K. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30837 · Cited by 27
The Benefits of Tight Glycemic Control in Type 2 Diabetes Mellitus
LeRoith, D., & Rayfield, E. J. (2007) · Clinical cornerstone · doi:10.1016/s1098-3597(07)80018-4 · Cited by 26
Reduced Endothelium-Dependent Relaxation to Anandamide in Mesenteric Arteries from Young Obese Zucker Rats
Lobato, N. S., Filgueira, F. P., Prakash, R., Giachini, F. R. C., Ergul, A., de Carvalho, M. H. C., Webb, R. C., Tostes, R. C., & Fortes, Z. B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063449 · Cited by 26
Obesity and the Endocannabinoid System: Circulating Endocannabinoids and Obesity
Matias, I., Gatta‐Cherifi, B., & Cota, D. (2012) · Current Obesity Reports · doi:10.1007/s13679-012-0027-6 · Cited by 26
“Endocannabinoids and Obesity As briefly mentioned before, several studies over the past few years have demonstrated that circulating endocannabinoids are elevated in obesity, as compared to normal weight, and positively correlated with different measures of adiposity, including waist circumference, body fat percentage…”
BackgroundInfluential
Acute Overactive Endocannabinoid Signaling Induces Glucose Intolerance, Hepatic Steatosis, and Novel Cannabinoid Receptor 1 Responsive Genes
Ruby, M. A., Nomura, D. K., Hudak, C. S. S., Barber, A., Casida, J. E., & Krauss, R. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026415 · Cited by 26
“Dysregulation of the endocannabinoid (EC) system has been linked to increased adiposity in humans by epidemiological and genetic data [2,3,4].”
Acute rimonabant treatment promotes protein synthesis in C2C12 myotubes through a CB1‐independent mechanism
Bacquer, O. L., Lanchais, K., Combe, K., Berghe, L. V. D., & Walrand, S. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30034 · Cited by 26
“…that the ECS reg- ulates insulin sensitivity in peripheral tissues, such as adipose tissue, liver, and skeletal muscle, and the overactivation of the ECS is associated with the development of obesity and diabetes (Bluher et al., 2006; D'Eon et al., 2008; Engeli et al., 2005; Matias et al., 2006).”
Background
Analysis of the oral microbiome during hormonal cycle and its alterations in menopausal women: the “AMICA” project
Tramice, A., Paris, D., Manca, A., Agudelo, F. A. G., Petrosino, S., Siracusa, L., Carbone, M., Melck, D. J., Raymond, F., & Piscitelli, F. (2022) · Scientific Reports · doi:10.1038/s41598-022-26528-w · Cited by 25
Fatty Acid Composition and Development of Hepatic Lipidosis During Food Deprivation—Mustelids as a Potential Animal Model for Liver Steatosis
Nieminen, P., Mustonen, A., Kärjä, V. J., Asikainen, J., & Rouvinen‐Watt, K. (2009) · Experimental Biology and Medicine · doi:10.3181/0806-rm-210 · Cited by 25
“The altered n-6/n-3 PUFA ratio may be important also in the activation of the endocannabinoid system, which is upregulated in human obesity (47).”
Background
Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk
Janero, D. R., Lindsley, L., Vemuri, K. V., & Makriyannis, A. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.608063 · Cited by 25
“Reported decreases in CB1R mRNA [74] and expression [77,80,84] levels and 2-AG content [77] in adipose tissue from obese individuals have been interpreted as evidence for a purported counter-regulatory mechanism that attempts to limit the obesity-related consequences of CB1R activation, which can be normalized to some…”
BackgroundInfluential
The Endocannabinoid System and the Control of Glucose Homeostasis
Nogueiras, R., Rohner‐Jeanrenaud, F., Woods, S. C., & Tschöp, M. H. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01692.x · Cited by 25
Endocannabinoids and Metabolic Disorders
Gatta‐Cherifi, B., & Cota, D. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-20825-1_13 · Cited by 31
Peripheral Metabolic Effects of Endocannabinoids and Cannabinoid Receptor Blockade
Engeli, S. (2008) · Obesity Facts · doi:10.1159/000114255 · Cited by 25
Endocannabinoids and Their Role in Fatty Liver Disease
Mallat, A., & Lotersztajn, S. (2010) · Digestive Diseases · doi:10.1159/000282100 · Cited by 25
Cannabinoid-1 receptor antagonists in type-2 diabetes
Scheen, A. J. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.08.005 · Cited by 25
Cannabinoid CB1 Receptors in the Intestinal Epithelium Are Required for Acute Western-Diet Preferences in Mice
Avalos, B., Argueta, D. A., Perez, P. A., Wiley, M. B., Wood, C. P., & DiPatrizio, N. V. (2020) · Nutrients · doi:10.3390/nu12092874 · Cited by 25
Mutation screen and association studies for the fatty acid amide hydrolase (FAAH) gene and early onset and adult obesity
Müller, T. D., Brönner, G., Wandolski, M., Carrie, J., Nguyen, T. T. H., Greene, B., Scherag, A., Grallert, H., Vogel, C. I. G., Scherag, S., et al. (2010) · BMC Medical Genetics · doi:10.1186/1471-2350-11-2 · Cited by 24
“In accordance to its pivotal role in degradation of anandamide, FAAH mRNA expression is decreased by 59% in adipose tissue of obese women, as compared to lean controls, whereas circulating levels of anandamide and 2-AG were increased by 35% and 52% respectively [12].”
Background
Evaluating the Association of FAAH Common Gene Variation with Childhood, Adult Severe Obesity and Type 2 Diabetes in the French Population
Durand, E., Lecœur, C., Delplanque, J., Benzinou, M., Degraeve, F., Boutin, P., Marre, M., Balkau, B., Charpentier, G., Froguel, P., et al. (2008) · Obesity Facts · doi:10.1159/000178157 · Cited by 24
Development of two synthetic routes to CE-178,253, a CB1 antagonist for the treatment of obesity
Brandt, T. A., Caron, S., Damon, D. B., DiBrino, J., Ghosh, A. K., Griffith, D. A., Kedia, S. B., Ragan, J. A., Rose, P. R., Vanderplas, B. C., et al. (2008) · Tetrahedron · doi:10.1016/j.tet.2008.10.067 · Cited by 24
Cardiovascular disease in obesity: A review of related risk factors and risk-reduction strategies
Aronne, L. J., Brown, W. V., & Isoldi, K. K. (2007) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.10.005 · Cited by 23
Endocannabinoid tone is higher in healthy lean South Asian than white Caucasian men
Kantae, V., Nahon, K. J., Straat, M. E., Bakker, L. E. H., Harms, A. C., van der Stelt, M., Hankemeier, T., Jazet, I. M., Boon, M. R., & Rensen, P. C. N. (2017) · Scientific Reports · doi:10.1038/s41598-017-07980-5 · Cited by 24
Diet‐dependent modulation of hippocampal expression of endocannabinoid signaling‐related proteins in cannabinoid antagonist‐treated obese rats
Rivera, P., Rojas, M. J. L., Pastor, A., Blanco, E., Pavón, F. J., Serrano, A., Crespillo, A., Vida, M., Grondona, J. M., Cifuentes, M., et al. (2012) · European Journal of Neuroscience · doi:10.1111/ejn.12012 · Cited by 23
“Thus, the ECS, through its actions on these brain structures, acts as a relevant mediator of the pathophysiological changes associated with feeding behavior alterations and metabolic disorders (Engeli et al., 2005; Bellocchio et al., 2010; Quarta et al., 2010).”
Background
Integrated physiology and pathophysiology of CB1-mediated effects of the endocannabinoid system
Piazza, P. V., Lafontan, M., & Girard, J. R. (2007) · Diabetes & Metabolism · doi:10.1016/j.diabet.2007.02.002 · Cited by 23
Novel aspects of adipocyte-induced skeletal muscle insulin resistance
Eckardt, K., Sell, H., & Eckel, J. (2008) · Archives of Physiology and Biochemistry · doi:10.1080/13813450802404761 · Cited by 24
“(2007) found an increased expression of CB1R mRNA in visceral fat tissue of obese patients, other working groups (Bluher et al., 2006; Engeli et al., 2005; Kempf et al., 2007) reported decreased levels in visceral and subcutaneous fat tissue compared to lean patients.”
Background
Cannabinoids, Chemical Senses, and Regulation of Feeding Behavior
Tarragón, E., & Moreno, J. J. (2018) · Chemical Senses · doi:10.1093/chemse/bjy068 · Cited by 23
Heritability and family-based GWAS analyses of the N -acyl ethanolamine and ceramide plasma lipidome
McGurk, K. A., Williams, S. G., Guo, H., Watkins, H. C., Farrall, M., Cordell, H. J., Nicolaou, A., & Keavney, B. D. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab002 · Cited by 24
Effects of Chronic Treatment With the CB1 Antagonist, Rimonabant on the Blood Pressure, and Vascular Reactivity of Obese Zucker Rats
Mingorance, C., de Sotomayor, M. A., Jiménez‐Palacios, F. J., Mochón, M. C., Casto, C., Marhuenda, E., & Herrera, M. D. (2009) · Obesity · doi:10.1038/oby.2009.20 · Cited by 23
Hydroxytyrosol Inhibits Cannabinoid CB1 Receptor Gene Expression in 3T3‐L1 Preadipocyte Cell Line
Tutino, V., Orlando, A., Russo, F., & Notarnicola, M. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25094 · Cited by 24
“The ECS modulates several central and peripheral functions and is usually silent, but it becomes transiently activated in stressful conditions (Andre and Gonthier, 2010).”
BackgroundInfluential
Endocannabinoids, FOXO and the metabolic syndrome: Redox, function and tipping point – The view from two systems
Nunn, A. V. W., Guy, G. W., & Bell, J. D. (2009) · Immunobiology · doi:10.1016/j.imbio.2009.03.005 · Cited by 22
“In obesity, both circulating AEA and 2-AG increased (Engeli et al. 2005).”
Background
The Acute Effect of Oleic- or Linoleic Acid-Containing Meals on Appetite and Metabolic Markers; A Pilot Study in Overweight or Obese Individuals
Naughton, S., Hanson, E. D., Mathai, M. L., & McAinch, A. J. (2018) · Nutrients · doi:10.3390/nu10101376 · Cited by 23
“Additionally, the endocannabinoid system is upregulated in obesity, which may further perpetuate excessive energy intake [17].”
Background
Pre-analytical challenges for the quantification of endocannabinoids in human serum
Kratz, D., Sens, A., Schäfer, S. M. G., Hahnefeld, L., Geißlinger, G., Thomas, D., & Gurke, R. (2022) · Journal of Chromatography B · doi:10.1016/j.jchromb.2022.123102 · Cited by 22
Hepatic targeting of the centrally active cannabinoid 1 receptor (CB1R) blocker rimonabant via PLGA nanoparticles for treating fatty liver disease and diabetes
Hirsch, S., Hinden, L., Naim, M. B.-D., Baraghithy, S., Permyakova, A., Azar, S., Nasser, T., Portnoy, E., Agbaria, M., Nemirovski, A., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.040 · Cited by 25
Fat-Rich Food Palatability and Appetite Regulation
Erlanson‐Albertsson, C. (2009) · Frontiers in neuroscience · doi:10.1201/9781420067767-c14 · Cited by 23
Weight loss and improved mood after aerobic exercise training are linked to lower plasma anandamide in healthy people
Oliveira, A. B., de Mello, M. T., Tufik, S. B., & Peres, M. F. P. (2018) · Physiology & Behavior · doi:10.1016/j.physbeh.2018.12.018 · Cited by 22
Influence of G1359A polymorphism of the cannabinoid receptor gene on anthropometric parameters and insulin resistance in women with obesity
de Luis, D. A., Sagrado, M. G., Aller, R., Izaola, O., & Conde, R. (2010) · Metabolism · doi:10.1016/j.metabol.2010.01.028 · Cited by 21
“Furthermore, the CB1 receptor is expressed in some peripheral human tissues studied in relation to the pathogenesis of obesity and obesityassociated metabolic disorders; and marked down-regulation of the fatty acid amide hydrolase gene expression was found in the adipose tissue of obese women, suggesting that adipose…”
Background
Effect of rimonabant, the cannabinoid CB1 receptor antagonist, on peripheral nerve in streptozotocin-induced diabetic rat
Liu, W. J., Jin, H. Y., Park, J. H., Baek, H. S., & Park, T. S. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.04.004 · Cited by 21
Endocannabinoid system and its implications for obesity and cardiometabolic risk
Nesto, R. W., & Mackie, K. (2008) · European Heart Journal Supplements · doi:10.1093/eurheartj/sum052 · Cited by 21
G1359A polymorphism of the cannabinoid receptor gene (CNR1) and insulin resistance in patients with diabetes mellitus type 2.
de Luis, D. A., Sagrado, M. G., Aller, R., Izaola, O., Conde, R., & Romero, E. (2010) · PubMed · Cited by 21
The cannabinoid ligand LH-21 reduces anxiety and improves glucose handling in diet-induced obese pre-diabetic mice
Romero‐Zerbo, S., Ruz‐Maldonado, I., Espinosa-Jiménez, V., Rafacho, A., Gómez-Conde, A. I., Salido, L. S., Cobo‐Vuilleumier, N., Gauthier, B. R., Tinahones, F. J., Persaud, S. J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-03292-w · Cited by 21
Inhibition of Endocannabinoid-Metabolizing Enzymes in Peripheral Tissues Following Developmental Chlorpyrifos Exposure in Rats
Buntyn, R. W., Alugubelly, N., Hybart, R., Mohammed, A. N., Nail, C. A., Parker, G. C., Ross, M. K., & Carr, R. L. (2017) · International Journal of Toxicology · doi:10.1177/1091581817725272 · Cited by 21
Endocannabinoids, endocannabinoid-like molecules and their precursors in human small intestinal lumen and plasma: does diet affect them?
Tagliamonte, S., Gill, C. I. R., Pourshahidi, L. K., Slevin, M. M., Price, R. K., Ferracane, R., Lawther, R., O’Connor, G., & Vitaglione, P. (2020) · European Journal of Nutrition · doi:10.1007/s00394-020-02398-8 · Cited by 25
Analysis of 14 endocannabinoids and endocannabinoid congeners in human plasma using column switching high-performance atmospheric pressure chemical ionization liquid chromatography–mass spectrometry
Sempio, C., Klawitter, J., Jackson, M., Freni, F., Shillingburg, R., Hutchison, K. E., Bidwell, L. C., Christians, U., & Klawitter, J. (2021) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03280-0 · Cited by 21
Effects of Chronic Antagonism of Endocannabinoid-1 Receptors on Glucose Tolerance and Insulin Action in Skeletal Muscles of Lean and Obese Zucker Rats
Lindborg, K. A., Jacob, S., & Henriksen, E. J. (2011) · Cardiorenal Medicine · doi:10.1159/000322826 · Cited by 21
“Obesity is known to cause dysregulation of the endocannabinoid system [ ,”
Background
Orosensory Detection of Dietary Fatty Acids Is Altered in CB1R−/− Mice
Brissard, L., Leemput, J., Hichami, A., Passilly‐Degrace, P., Maquart, G., Demizieux, L., Degrace, P., & Khan, N. A. (2018) · Nutrients · doi:10.3390/nu10101347 · Cited by 21
Peripheral Endocannabinoid System Activity in Patients Treated With Sibutramine
Engeli, S., Heusser, K., Janke, J., Gorzelniak, K., Bátkai, S., Pacher, P., Harvey-White, J. D., Luft, F. C., & Jordan, J. (2008) · Obesity · doi:10.1038/oby.2008.47 · Cited by 21
“Similarly, 5% weight loss through caloric restriction had no effect on peripheral ECS activity (7).”
BackgroundMethodInfluential
[Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].
Scheen, A. J., Gaal, L. G. V., Després, J., Pi-Sunyer, X., Golay, A., & Hanotin, C. (2006) · PubMed · Cited by 21
Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host-targeting agents
Shahidi, M., Tay, E. S. E., Read, S. A., Ramezani–Moghadam, M., Chayama, K., George, J., & Douglas, M. W. (2014) · Journal of General Virology · doi:10.1099/vir.0.067231-0 · Cited by 22
“The endocannabinoid system is an important regulator of hepatic lipid metabolism; signalling through the hepatic cannabinoid 1 (CB1) receptor induces hepatic steatosis in both clinical and experimental studies (Engeli et al., 2005; Osei-Hyiaman et al., 2005, 2008).”
Background
The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice
Malfitano, A. M., Laezza, C., Galgani, M., Matarese, G., D’Alessandro, A., Gazzerro, P., & Bifulco, M. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.11.008 · Cited by 20
Behavioral, Metabolic, and Immune Consequences of Chronic Alcohol or Cannabinoids on HIV/AIDs: Studies in the Non-Human Primate SIV Model
Molina, P. E., Amedee, A. M., Winsauer, P. J., Nelson, S., Bagby, G., & Simon, L. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-015-9599-8 · Cited by 20
Endocannabinoids and the cardiovascular response to stress
O’Sullivan, S. E., Kendall, P. J., & Kendall, D. A. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111408457 · Cited by 20
“Obesity, which is a significant physical stressor, is also associated with increased 2-AG levels (Côté et al., 2007; Engeli et al., 2005).”
Background
Emerging drugs for obesity therapy
Zanella, M. T., & Filho, F. F. R. (2009) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302009000200019 · Cited by 20
New vistas for treatment of obesity and diabetes? Endocannabinoid signalling and metabolism in the modulation of energy balance
Lipina, C., Rastedt, W., Irving, A. J., & Hundal, H. S. (2012) · BioEssays · doi:10.1002/bies.201200031 · Cited by 19
“Indeed, circulating levels of anandamide and 2-AG do correlate positively with non-esterified free fatty acid (NEFA) and triglyceride levels which are found to be higher in obese human subjects compared to lean individuals [2, 4, 5, 15, 81].”
Background
Chronic activation of cannabinoid receptorsin vitrodoes not compromise mouse islet function
Vilches‐Flores, A., Hauge-Evans, A. C., Jones, P. M., & Persaud, S. J. (2012) · Clinical Science · doi:10.1042/cs20120447 · Cited by 20
The effects of obesity, diabetes and metabolic syndrome on the hydrolytic enzymes of the endocannabinoid system in animal and human adipocytes
Cable, J. C., Tan, G. D., Alexander, S. P. H., & O’Sullivan, S. E. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-43 · Cited by 20
“N-arachidonoylethanolamide (anandamide, AEA) * Correspondence: mbzso@nottingham.ac.uk 1Division of Medical Sciences & Graduate Entry Medicine, School of Medicine, Faculty of Medicine & Health Sciences, University of Nottingham, Royal Derby Hospital Centre, Uttoxeter Road, Derby, DE22 3DT, UK Full list of author inform…”
BackgroundInfluential
Activity-based reporter assays for the screening of abused substances in biological matrices
Cannaert, A., Vandeputte, M. M., Wille, S. M. R., & Stove, C. P. (2019) · Critical Reviews in Toxicology · doi:10.1080/10408444.2019.1576588 · Cited by 20
“Although in some conditions (eating disorders, obesity, schizophrenia, post-exercise) the endocannabinoid concentrations can rise, this will never be to an extent that this would lead to interference (<10 pmol/ mL) (De Marchi et al. 2003; Engeli et al. 2005; Heyman et al. 2012).”
Background
Childhood Obesity and the Role of Dopamine D2 Receptor and Cannabinoid Receptor-1 Gene Polymorphisms
Araz, N. Ç., Nacak, M., Balcı, S. O., Benlier, N., Araz, M., Pehlıvan, S., Balat, A., & Aynacıoğlu, A. Ş. (2012) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2012.0244 · Cited by 20
“This system regulates appetite via the activation of cannabinoid receptor-1 (CNR1) (Engeli et al. , 2005; Pagotto et al. , 2006).”
Gene-diet interactions with polymorphisms of the MGLL gene on plasma low-density lipoprotein cholesterol and size following an omega-3 polyunsaturated fatty acid supplementation: a clinical trial
Ouellette, C., Rudkowska, I., Lemieux, S., Lamarche, B., Couture, P., & Vohl, M. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-86 · Cited by 20
“Circulating 2-AG levels in the plasma have been correlated positively with BMI and waist girth, as well as with plasma TG levels [50], while another study found that 2-AG levels were increased by 52% in obese women [51].”
Background
Prejunctional and peripheral effects of the cannabinoid CB1 receptor inverse agonist rimonabant (SR 141716)
van Diepen, H. C., Schlicker, E., & Michel, M. C. (2008) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-008-0327-2 · Cited by 20
The endocannabinoid system and cardiometabolic risk
Szmitko, P. E., & Verma, S. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.03.011 · Cited by 21
Comparative genetics of the central nervous system in epigean and hypogean Astyanax mexicanus
Strickler, A. G., & Soares, D. (2011) · Genetica · doi:10.1007/s10709-011-9557-1 · Cited by 19
“Changes in cannabinoids levels have been shown to underlie obesity in rats (Harrold 2002) and humans ( Engeli et al. 2005 ).”
Background
Meta-analyses between 18 candidate genetic markers and overweight/obesity
Tang, L., Ye, H., Hong, Q., Chen, F., Wang, Q., Xu, L., Bu, S., Liu, Q., Ye, M., Wang, D. W., et al. (2014) · Diagnostic Pathology · doi:10.1186/1746-1596-9-56 · Cited by 19
“CNR1 is shown to regulate the endocannabinoid system that might stimulate the metabolism of lipogenesis through central and peripheral mechanisms [15,16].”
Background
Therapeutic Applications for Agents that Act at CB1 and CB2 Receptors
Pertwee, R. G., & Thomas, A. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-503-9_13 · Cited by 20
“It has also been found, however, that CB1 mRNA expression is downregulated in the adipose tissue of obese women [193], and that body weight increases induced in rats by a palatable diet are associated with a decrease in the density of CB1-binding sites in extrahypothalamic brain areas, including the nucleus accumbens…”
Background

Authors: Engeli, S., Böhnke, J., Feldpausch, M., Gorzelniak, K., Janke, J., Bátkai, S., Pacher, P., Harvey-White, J., Luft, F. C., Sharma, A. M., & Jordan, J.
Affiliations: Helios Hospital Berlin-Buch (DE)
Franz Volhard Clinical Research Center, Charité Campus Buch, and HELIOS Klinikum Berlin, Berlin, Germany
Laboratory of Physiologic Studies, National Institute on Alcohol Abuse & Alcoholism, National Institutes of Health, Bethesda, Maryland
National Institutes of Health (US)
McMaster University (CA)
ORCID: Engeli, Stefan
Luft, Friedrich C.
Sharma, Arya M.
Jordan, Jens
Venue: Diabetes
Publisher: American Diabetes Association
Published: 2005-10-01
Volume: 54
Issue: 10
Pages: 2838-2843
ISSN: 0012-1797 (ISSN-L)
1939-327X
DOI: 10.2337/diabetes.54.10.2838
PMC: PMC2228268
OpenAlex: W2162112945
Cited by: 686
References: 37
Citations by year: 2026: 11 · 2025: 14 · 2024: 20 · 2023: 19 · 2022: 20 · 2021: 30 · 2020: 29 · 2019: 24 · 2018: 30 · 2017: 30 · 2016: 15 · 2015: 31 · 2014: 29 · 2013: 29 · 2012: 33
FWCI: 38.06
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Diabetes (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
Funders: Sanofi
Bundesministerium für Bildung und Forschung
National Institutes of Health
National Institute on Alcohol Abuse and Alcoholism (Z01AA000375)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords: obesity, cannabinoid type 1 receptor, fatty acid amide hydrolase, anandamide, 2-arachidonoylglycerol, adipose tissue, weight loss, human adipocytes, type 2 diabetes risk
MeSH terms: Fatty Acid Amide Hydrolases, Adipose Tissue, Amidohydrolases, Arachidonic Acids, Body Composition, Female, Glycerides, Humans, Middle Aged, Obesity, RNA, Messenger, Weight Loss, Gene Expression, Body Mass Index, Linear Models, Postmenopause, Reverse Transcriptase Polymerase Chain Reaction, Receptor, Cannabinoid, CB1, Polyunsaturated Alkamides, Cannabinoid Receptor Modulators, Endocannabinoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Activation of the Peripheral Endocannabinoid System in Human Obesity

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks